



Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

October 5, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Oct. 5, 2022-- [Aldeyra Therapeutics, Inc.](#) (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to report top-line results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection, United States Pharmacopeia) for intravitreal administration in patients with proliferative vitreoretinopathy (PVR), a rare, sight-threatening ocular disease with no approved therapy.

The dial-in numbers are (844) 200-6205 for domestic callers and (646) 904-5544 for international callers. The access code is 005042. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra's website at [ir.aldeyra.com](#).

After the live webcast, the event will remain archived on Aldeyra's website for 90 days.

About Aldeyra

Aldeyra is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (methotrexate injection, United States Pharmacopeia) for intravitreal administration, in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit <https://www.aldeyra.com> and follow us on [LinkedIn](#), [Facebook](#), and [Twitter](#).

View source version on [businesswire.com](#): <https://www.businesswire.com/news/home/20221005005669/en/>

Investor & Media:

Scott Solomon
Sharon Merrill Associates, Inc.
Tel: (857) 383-2409
ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.